DGAP-News: Phase III Familial Adenomatous Polyposis (FAP)

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 5, 2013 at 6:15 AM

DGAP-News: Phase III Familial Adenomatous Polyposis (FAP) Trial Now Open for Enrollment

DGAP-News: Cancer Prevention Pharmaceuticals, Inc. / Phase III Familial Adenomatous Polyposis (FAP) Trial Now Open for Enrollment 05.12.2013 / 12:00 --------------------------------------------------------------------- TUCSON, Ariz., 2013-12-05 12:00 CET (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a double-blind, randomized, Phase III trial of the efficacy and safety of CPP-1X/sulindac (eflornithine/sulindac) compared with CPP-1X and sulindac as single agents in 150 patients with Familial Adenomatous Polyposis. Each patient will receive daily treatment for two years to minimize the occurrence and/or recurrence of problematic polyps and tumors associated with this debilitating disease. The trial is being conducted at 8 North American and 4 European clinical trial sites. 'The design of this trial is particularly exciting,' noted Alfred Cohen, MD and Chief Medical Officer of CPP. 'Rather than count polyps, which has been the past indicator of clinical success in pharmacoprevention trials in FAP, we have designed our trial to assess meaningful clinical outcomes in these patients. With a successful outcome in this study, we will have real evidence of patient benefit.' Jeff Jacob, Chief Executive Officer of CPP, added, 'The initiation of this trial is a huge milestone for our Company and for patients with FAP. Taking specific guidance from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) on trial design, we and our expert advisors believe the drug could change the treatment paradigm in FAP by delaying or eliminating surgical interventions and/or cancer.' About Familial Adenomatous Polyposis (FAP) Familial adenomatous polyposis (FAP) is an inherited disorder characterized by cancer of the large intestine (colon) and rectum. People with the classic type of FAP may begin to develop multiple noncancerous (benign) growths (polyps) in the colon as early as their teenage years. Currently, there are no approved pharmacologic treatments for FAP. Unless the colon is removed - the only real treatment option - these polyps will become malignant (cancerous). The average age at which an individual develops colon cancer in classic FAP is 39 years. Some people have a variant of the disorder, called attenuated FAP, in which polyp growth is delayed. The average age of colorectal cancer onset for attenuated FAP is 55 years. In people with classic FAP, the number of polyp's increases with age, and over time, hundreds to thousands of polyps carpet the colon. Also of particular significance are noncancerous growths called desmoid tumors. These fibrous tumors usually occur in the tissue covering the intestines and may be provoked by surgery to remove the colon. Desmoid tumors tend to recur after they are surgically removed. In both classic FAP and its attenuated variant, benign and malignant tumors are sometimes found in other places in the body, including the duodenum (a section of the small intestine), stomach, bones, skin, and other tissues. If left untreated, FAP leads to colorectal cancer and death. About Cancer Prevention Pharmaceuticals, Inc. (CPP) CPP is developing therapeutics that reduce the risk of cancer. CPP's approach has been used with great success in other disease categories such as cardiovascular, neurovascular and infectious disease. Agents that target pre-disease states have helped reduce death rates from these conditions by 50%-70% over the past 30 years. Just as these other prevention therapies represent the largest-selling drug classes on the market today, CPP believes there is even more potential for therapies that reduce the risk of cancer. In addition to this Phase III trial CPP, in collaboration with the National Cancer Institute (NCI) and the SWOG cancer research cooperative group, is sponsoring a large 1,340 patient Phase III trial in colon cancer survivors. CPP is also working collaboratively with non-profit groups to support trials in neuroblastoma--treating and preventing--with three active clinical trials. Additional information is available at www.canprevent.com. Forward-Looking Statements This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the planned Phase III trial of the CPP-1X/sul combination therapy as well as the company's focus, collaborative partners, and independent and partnered product candidates. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT: Jeffrey Jacob Chief Executive Officer 520-908-7774 jjacob@canprevent.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 05.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Cancer Prevention Pharmaceuticals, Inc. United States ISIN: US9901623564 End of News DGAP News-Service --------------------------------------------------------------------- 243330 05.12.2013

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CourseArc Partners with Colleges for ADA Compliance

CourseArc's Landmark Deal with Public Colleges Well, slap me silly and call me a believer—looks like CourseArc just locked down a heck of a gig with a public college system that's head-over-heels squirming to meet shiny new accessibility demands. Nearly 200,000 learners are waiting at their gates, and this agreement is the lifeline for colleges to not only stay afloat...

AI Agents Race: 10M Downloads Spark Competitive Fire

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

York Space Systems Faces Securities Law Class Action

Unexpected Turbulence at York Space Systems Just when you thought things might be smooth sailing, York Space Systems (NYSE: YSS) finds itself on the hot seat. This fledgling aerospace player is now wrangling with a class action lawsuit for allegedly breaking federal securities laws. Call it a wake-up call from DJS Law Group encouraging investors who've had their fingers...

Rublev's Tennis Meet Boosts Inclusivity for Autism

Tennis Bridging Worlds in the Heart of Kazakhstan When Andrey Rublev, a powerhouse in the world of tennis, wields his racket for more than just a win, you know something special is brewing. During the Almaty Open ATP 250 tournament, he did exactly that, sharing the court not with rivals, but with ten spirited children from the Asyl Miras Autism Center. This heartwarming...

AMTD IDEA Group: Expanding Its Global Reach

AMTD IDEA's Expansive Global Footprint While the rest of the market whirls, AMTD IDEA Group (NYSE: AMTD) is steadying itself with a comprehensive expansion that, quite frankly, demands a second look. Between weaving global media threads and dipping their toes into every alluring venture space, they've formed a tapestry not many could replicate. With facilities stretching...

Shadeform Debuts Flex VMs, Revolutionizing GPU Utilization

GPU Utilization Gets a New Spin with Flex VMs Folks, listen up: Shadeform just fired up something slick with its new Flex VMs. And, let me tell you, in today's market where GPU capacity is vanishing faster than free hotcakes on a Sunday morning, this might well be a game changer. Shadeform’s the name to remember, teaming up data center veterans with peeps who need to...

Scrutinizing M&A Deals: VREX, HZO, SYNA Under Fire?

Alignment or Deception: The M&A Alarm Bells Investors, strap in, because the world of mergers and acquisitions is lighting up like a pinball machine, and today's spotlight's on Varex Imaging Corporation (NASDAQ: VREX), MarineMax (NYSE: HZO), and Synaptics Incorporated (NASDAQ: SYNA). Halper Sadeh LLC, known for their tenacity in championing shareholder rights, has brought...

SKF Q3 2026: Margins Edge Up Amid Strategic Shifts

Cracking Open SKF's Latest Quarterly Numbers Ever seen a company limber up for a big change while tiptoeing through a minefield? That’s SKF for you in this third quarter ending September 2026. Imagine them trying to juggle a spinning platter of growth, strategic separation, and robust margins, all while balancing a wobbly market. A Close Look at Q3's Financial Feats...

University of Phoenix Lowers Costs for Transfer Students

The Pocket-Saving Game of Transfer Credits Here's the buzz: the University of Phoenix is putting some serious coin back into students' pockets through transfer credits. We're looking at more than $12,010 in savings per student, thanks to these policies, which is no chump change by any stretch. As over 900,000 credits were tossed into the pot, the savings side of education...